These updates are republished press releases and communications from members of the Science|Business Network. Network Updates can be sent to [email protected] and [email protected]. To know if your content piece qualifies as Network Update, check the editorial guidelines here.

Cambridge: First of new generation of cancer drugs granted European approval

A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.

07 Jan 2015

ETH Zürich: Fertile ground for innovative spirit

A total of 22 new companies were founded in 2014 by researchers from ETH Zurich. These spin-offs are among the most successful in Switzerland. One of the year's highlights was Covagen, which was acquired for over CHF 200 million. The latest figures also reveal that the university is on the right track with its promotion programmes.
07 Jan 2015